This is the authors' abstract. We don't add key points for this paper.
PURPOSE Preclinical data suggest synergy between immune checkpoint blockade, poly (ADP-ribose) polymerase inhibition, and radiation therapy (RT). This randomized phase II study evaluated the safety of pembrolizumab with standard-of-care (SOC) RT and androgen-deprivation therapy (ADT), with or without short-course olaparib, in high-risk or very high-risk localized prostate cancer. METHODS Patients were randomly assigned 1:1 to arm 1 (pembrolizumab + olaparib 200 mg twice a day + SOC RT/ADT) or arm 2 (pembrolizumab + SOC RT/ADT). Safety was assessed per Common Terminology Criteria for Adverse Events v5.0. The primary end point was prostate-specific antigen nadir ≤0.06 ng/mL within 6 months following RT; the planned sample size was 64. This report presents a prespecified safety analysis. RESULTS Eighteen patients were enrolled; 1 withdrew before treatment, leaving 17 who received ≥1 cycle of pembrolizumab (arm 1, N = 7; arm 2, N = 10). Median follow-up was 260 days in arm 1 and 236 days in arm 2. Median pembrolizumab exposure was nine cycles (range, 2-34), and all patients in arm 1 completed three cycles of olaparib. All patients experienced ≥1 adverse event (AE), most grade 1 to 2. Common events included fatigue, diarrhea, lymphopenia, anemia, hypertension, and hyperglycemia. Creatinine elevation was numerically more common in the olaparib arm. Grade ≥3 events occurred in both arms and were mainly laboratory abnormalities. Three serious AEs occurred, including 1 patient with immune-mediated pneumonitis that resulted in death. Median time to first immune-mediated AE was 90.5 days and 64 days for grade ≥3 events. No unexpected safety signals were observed. CONCLUSION Pembrolizumab with RT/ADT, with or without short-course olaparib, was feasible. No clear short-term safety signal attributable to olaparib was observed. One treatment-related death from immune-mediated pneumonitis occurred, notable in this curative-intent population. Ongoing follow-up will evaluate efficacy (ClinicalTrials.gov identifier: NCT05568550 ).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Myint et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: